Table 5.
Effect of CaP supplementation on faecal excretion of bile acids.
| Parameter | Placebo | CaP | Change |
|---|---|---|---|
| iLCA | 39 ± 24 | 45 * ± 28 | 6 ± 21 |
| (mg/day) | (33–45) | (38–52) | (0.3–11.0) |
| LCA | 54 ± 31 | 69 * ± 36 | 15 # ± 24 |
| (mg/day) | (47–62) | (60–78) | (8.4–20.8) |
| iDCA | 34 ± 24 | 37 ± 40 | 3 ± 28 |
| (mg/day) | (28–40) | (27–47) | (−4.1–9.9) |
| DCA | 98 ± 43 | 135 * ± 73 | 36 ± 56 |
| (mg/day) | (88–109) | (116–153) | (22.2–50.5) |
| CDCA | 6 ± 4 | 7 * ± 5 | 1 # ± 4 |
| (mg/day) | (5–7) | (6–8) | (0.02–2.3) |
| CA | 10 ± 12 | 12 ± 11 | 2 ± 11 |
| (mg/day) | (7–13) | (9–15) | (−0.9–4.8) |
| 12keto DCA | 8 ± 7 | 11 * ± 12 | 4 ± 9 |
| (mg/day) | (6–9) | (8–15) | (1.5–6.0) |
n (studies) = 2; n (subjects) = 62; mean ± standard deviation; (95% confidence interval); * significantly different to placebo (paired Student’s t-test, p ≤ 0.05); # significantly different to zero (one-way ANOVA, p ≤ 0.05); CaP: three–four weeks´ intervention with Ca5(PO4)3OH(pentacalcium hydroxy-trisphosphate); BA: bile acids, iLCA: iso-lithocholic acid; LCA: lithocholic acid; iDCA: iso-deoxycholic acid; DCA: deoxycholic acid; CDCA: chenodeoxycholic acid, CA: cholic acid, 12keto DCA: 12keto-deoxycholic acid; primary BA: sum of CDCA and CA; secondary BA: sum of iLCA, LCA, iDCA, DCA and 12keto DCA.